Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Alteryx Therapeutics Ltd in metadata) covers the quarter ended December 31, 2015, and the six-month period ending on that date. The registrant is an Australian entity admitted on the basis of commitments, reporting under Rule 4.7B Appendix 4C. The filing was signed on January 30, 2015.
Key Financial Metrics
| Metric | Current Quarter ($A'000) | Year to Date ($A'000) |
|---|---|---|
| Receipts from Customers | 0 | 0 |
| Net Operating Cash Flows | (4,055) | (8,423) |
| Net Investing Cash Flows | (9) | (22) |
| Net Financing Cash Flows | (96) | (104) |
| Net Decrease in Cash | (4,160) | (8,549) |
| Cash at End of Period | 29,053 | 29,053 |
| Loan Facilities Available | 0 | 0 |
The company reported no revenue from customers. Operating cash outflows were primarily driven by research and development ($2,670k for the quarter; $5,829k YTD) and staff costs ($820k for the quarter; $1,490k YTD). The company holds $29.053 million in cash, comprising $26.053 million on hand/at bank and $3.0 million in deposits at call.
Material Changes and Activities
- Cash Position: Cash reserves decreased by $4.16 million during the quarter and $8.55 million year-to-date due to ongoing operational burn.
- Non-Cash Financing: On October 3, 2014, the company issued 1,000,000 unlisted options exercisable at AUD$0.34 under an Employee Incentive Scheme and Consulting Agreement.
- Related Party Payments: The company paid $251,000 to directors and associates during the quarter for salaries, fees, and consulting at normal commercial rates.
Guidance, Risks, and Commentary
The filing does not contain forward-looking guidance, management commentary on future outlook, or specific risk factors beyond the standard compliance statements. The report focuses strictly on cash flow reconciliation and financing activities for the period. There are no borrowings or credit standby arrangements currently in use.
Investor Verification Checklist
- Verify the discrepancy between the metadata company name ("Alteryx Therapeutics Ltd") and the filing registrant ("Prana Biotechnology Limited").
- Confirm the sustainability of the $29.053 million cash balance given the quarterly burn rate of approximately $4.16 million and zero revenue.
- Review the terms of the 1,000,000 options issued in October 2014 to assess potential dilution.
- Monitor the status of research and development expenditures to determine if they align with expected clinical or product milestones.